These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9491873)

  • 1. A randomized controlled study of the effects of 17beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women.
    Mijatovic V; Kenemans P; Jakobs C; van Baal WM; Peters-Muller ER; van der Mooren MJ
    Obstet Gynecol; 1998 Mar; 91(3):432-6. PubMed ID: 9491873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels.
    Mijatovic V; Kenemans P; Netelenbos C; Jakobs C; Popp-Snijders C; Peters-Muller ER; van der Mooren MJ
    Fertil Steril; 1998 May; 69(5):876-82. PubMed ID: 9591496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.
    Chiantera V; Sarti CD; Fornaro F; Farzati A; De Franciscis P; Sepe E; Borrelli AL; Colacurci N
    Menopause; 2003; 10(4):286-91. PubMed ID: 12851511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy and plasma homocysteine levels.
    van Baal WM; Smolders RG; van der Mooren MJ; Teerlink T; Kenemans P
    Obstet Gynecol; 1999 Oct; 94(4):485-91. PubMed ID: 10511346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone replacement influences homocysteine levels in the methionine-loading test: a randomized placebo controlled trial in postmenopausal women.
    Smolders RG; de Meer K; Kenemans P; Teerlink T; Jakobs C; van der Mooren MJ
    Eur J Obstet Gynecol Reprod Biol; 2004 Nov; 117(1):55-9. PubMed ID: 15474245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual effect of E2 and dydrogesterone on insulin sensitivity in post-menopausal women.
    Soranna L; Cucinelli F; Perri C; Muzj G; Giuliani M; Villa P; Lanzone A
    J Endocrinol Invest; 2002 Jun; 25(6):547-50. PubMed ID: 12109627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term effects of low-dose 17beta-estradiol and dydrogesterone hormone replacement therapy on 24-h ambulatory blood pressure in hypertensive postmenopausal women: a 1-year randomized, prospective study.
    Kaya C; Dinçer Cengiz S; Cengiz B; Akgün G
    Climacteric; 2006 Dec; 9(6):437-45. PubMed ID: 17085376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women.
    Mijatovic V; Kenemans P; Netelenbos JC; Peters-Muller ER; van Kamp GJ; Voetberg GA; van de Weijer PH; van der Mooren MJ
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3543-7. PubMed ID: 9360504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women.
    van der Mooren MJ; Wouters MG; Blom HJ; Schellekens LA; Eskes TK; Rolland R
    Eur J Clin Invest; 1994 Nov; 24(11):733-6. PubMed ID: 7890010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women.
    Foster RH; Balfour JA
    Drugs Aging; 1997 Oct; 11(4):309-32. PubMed ID: 9342560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
    Milewicz T; Kostecka A; Rogatko I; Sztefko K; Kwiatkowska-Panek E; Radowick S; Krzysiek J
    Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequentially combined hormone replacement therapy reduces impedance to flow within the uterine and central retinal arteries in healthy postmenopausal women.
    van Baal WM; Kenemans P; Stehouwer CD; Peters-Muller ER; van Vugt JM; van der Mooren MJ
    Am J Obstet Gynecol; 1999 Dec; 181(6):1365-73. PubMed ID: 10601914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover.
    de Valk-de Roo GW; Netelenbos JC; Peters-Muller IR; Voetberg GA; van de Weijer PH; Bouman AA; Popp-Snijders C; Kenemans P
    Maturitas; 1997 Dec; 28(2):153-62. PubMed ID: 9522323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels.
    Smolders RG; van der Mooren MJ; Teerlink T; Merkus JM; Kroeks MV; Franke HR; Stehouwer CD; Kenemans P
    Fertil Steril; 2003 Feb; 79(2):261-7. PubMed ID: 12568832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women.
    Gaspard UJ; Wery OJ; Scheen AJ; Jaminet C; Lefebvre PJ
    Climacteric; 1999 Jun; 2(2):93-100. PubMed ID: 11910673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of hormone replacement therapy on homocysteine and echocardiography in postmenopausal women].
    Hui Y; Wu Y; Xiao L; Tang Z; Wu Y; Li Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):598-600. PubMed ID: 12487933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women.
    Stevenson JC; Rioux JE; Komer L; Gelfand M
    Climacteric; 2005 Dec; 8(4):352-9. PubMed ID: 16390770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral 17beta-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women.
    Pornel B; Chevallier O; Netelenbos JC
    Menopause; 2002; 9(3):171-8. PubMed ID: 11973440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine.
    Os I; Os A; Sandset PM; Bølling S; Seljeflot I; Djurovic S; Westheim A
    Cardiology; 2002; 98(1-2):6-12. PubMed ID: 12373040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral estradiol decreases plasma homocysteine, vitamin B6, and albumin in postmenopausal women but does not change the whole-body homocysteine remethylation and transmethylation flux.
    Smolders RG; de Meer K; Kenemans P; Jakobs C; Kulik W; van der Mooren MJ
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2218-24. PubMed ID: 15671107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.